MarketPeel
Insider Trading Intelligence
Pricing
…
AS

Adam K. Stern

MTNB
DIRECTOR · MATINAS BIOPHARMA HOLDINGS, INC. · CIK 0001403497
FILING MIX · LIFETIME89%/11%
BUYS
39
SELLS
5
TOTAL VALUE
$607.7K
COMPANIES
3
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
3,351,599
AVG SELL PX
—
TRADE KIND
SHOWING 44 / 44
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
21 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Adam K. Stern, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d21+66.67%+6.87%+1.45%+5.42%+5.69%—
14d21+71.43%+6.10%+2.21%+3.89%+11.16%—
30d21+71.43%+13.95%+4.03%+9.92%+7.06%—
60d21+61.90%+46.60%+7.21%+39.39%+2.26%—
90d21+57.14%+52.79%+10.26%+42.53%-3.31%—
180d21+76.19%+69.68%+18.91%+50.77%+51.69%—
1y21+57.14%+90.62%+34.92%+55.70%-2.25%—
2y21(1 pending)+30.00%-30.11%+30.17%-60.29%-75.51%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
MTNB · 3,301,983 shares · as of Aug 21, 2020
0825,4961,650,9922,476,4873,301,983SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 39 buys / 5 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VIVS
VIVOSIM LABS, INC.
PURCHASEGRANT
Stock grant
15,000——19,899Jan 27, 2026Jan 29, 2026 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
20,000——29,717Sep 11, 2025Sep 15, 2025 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
100$1,000.00$100.0K0Jan 7, 2025Jan 10, 2025 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
70,000——194,341Mar 6, 2024Mar 8, 2024 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
250$1,000.00$250.0K250Feb 15, 2024Mar 1, 2024 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
55,000——124,341May 18, 2022May 20, 2022 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
619——69,341Mar 1, 2021Mar 3, 2021 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
619——68,772Feb 3, 2021Feb 5, 2021 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
43,850——68,103Jan 19, 2021Jan 21, 2021 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
43,850——68,103Jan 19, 2021Mar 31, 2021 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
619——24,253Jan 4, 2021Jan 6, 2021 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
619——23,634Dec 2, 2020Dec 4, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
619——23,015Nov 2, 2020Nov 4, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
502——502Oct 27, 2020Oct 28, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
112,365——112,365Oct 27, 2020Oct 28, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
619——22,396Oct 2, 2020Oct 5, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
639$6.66$4.3K21,777Sep 3, 2020Sep 4, 2020 ↗View →
MTNB
MATINAS BIOPHARMA HOLDINGS, INC.
PURCHASE
20,000$0.83$16.6K3,301,983Aug 21, 2020Aug 24, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
639$6.66$4.3K21,138Aug 3, 2020Aug 24, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
1,450——20,499Jul 20, 2020Jul 22, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
22,108——22,108Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
SALE
25,676——0Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
SALE
1,525——0Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
SALE
253,911——0Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
2,633——2,633Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
SALE
10,086——0Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
1,593——1,593Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
231,383——231,383Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
36,900——36,900Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
807——807Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASEGRANT
Stock grant
1,244——1,244Jul 8, 2020Jul 10, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
639$6.66$4.3K19,049Jul 3, 2020Jul 6, 2020 ↗View →
MTNB
MATINAS BIOPHARMA HOLDINGS, INC.
PURCHASE
25,500——3,281,983Jun 23, 2020Jun 24, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
1,500$5.89$8.8K18,410Jun 8, 2020Jun 9, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
500$5.91$3.0K15,500Jun 8, 2020Jun 9, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
500$5.88$2.9K2,500Jun 8, 2020Jun 9, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
639$6.66$4.3K16,910Jun 3, 2020Jun 5, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
639$6.66$4.3K16,271May 7, 2020May 8, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
639$6.66$4.3K14,993Apr 20, 2020Apr 22, 2020 ↗View →
MTNB
MATINAS BIOPHARMA HOLDINGS, INC.
SALE
952,676——0Apr 3, 2020Apr 8, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
493——14,993Apr 3, 2020Apr 7, 2020 ↗View →
MTNB
MATINAS BIOPHARMA HOLDINGS, INC.
PURCHASE
278,407$0.50$139.2K1,337,399Apr 3, 2020Apr 8, 2020 ↗View →
DRIO
DARIOHEALTH CORP.
PURCHASE
14,500$3.80$55.1K14,500Mar 20, 2020Mar 23, 2020 ↗View →
MTNB
MATINAS BIOPHARMA HOLDINGS, INC.
PURCHASE
10,000$0.65$6.5K10,000Mar 17, 2020Mar 18, 2020 ↗View →
Other insiders · MTNB
Loading peer insiders…
About this filer
CIK 0001403497
ROLE
Director
PRIMARY
MTNB
COMPANIES
3
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001403497DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback